Evidence map›Paper›PMID 35969473›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

What can We Learn From High-Performing Screening Programs to Increase Bowel Cancer Screening Participation in Australia?

Louisa Flander, Evelien Dekker, Berit Andersen, Mette Bach Larsen, Robert J Steele, Nea Malila, Tytti Sarkeala, Manon van der Vlugt, Clasine de Klerk, Bart Knottnerus and 8 more

Open access · goldAbstract read
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 5 countries.

Louisa FlanderCentre for Epidemiology and Biostatistics, School of Population and Global Health, 85084The University of Melbourne, Parkville, VIC, Australia.ORCID https://orcid.org/0000-0003-0824-9364
Evelien DekkerDepartment of Gastroenterology and Hepatology, 26066Amsterdam UMC, AZ Amsterdam, Netherlands.
Berit AndersenUniversity Research Clinic for Cancer Screening, Department of Public Health Programmes, 53198Randers Regional Hospital, Randers, Denmark.
Mette Bach LarsenUniversity Research Clinic for Cancer Screening, Department of Public Health Programmes, 53198Randers Regional Hospital, Randers, Denmark.
Robert J SteeleNinewells Hospital & Medical School, 3042University of Dundee, Dundee, UK.
Nea MalilaFinnish Cancer Registry, Helsinki, Finland.
Tytti SarkealaFinnish Cancer Registry, Helsinki, Finland.
Manon van der VlugtDepartment of Gastroenterology and Hepatology, 26066Amsterdam UMC, AZ Amsterdam, Netherlands.
Clasine de KlerkDepartment of Gastroenterology and Hepatology, 26066Amsterdam UMC, AZ Amsterdam, Netherlands.
Bart Knottnerus8123Netherlands Institute for Health Services Research (Nivel), Utrecht, Netherlands.
Lucinda Bertels113896Erasmus School of Health Policy and Management, Rotterdam, Netherlands.
Anke WoudstraDepartment of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Manon C W SpaanderDepartment of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, Netherlands.
Mirjam FransenDepartment of Public and Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health Research Institute 1105AZ Amsterdam, Netherlands.
Sirpa HeinavaaraFinnish Cancer Registry, Helsinki, Finland.
Mary DillonCentre for Epidemiology and Biostatistics, School of Population and Global Health, 85084The University of Melbourne, Parkville, VIC, Australia.
Driss Ait OuakrimCentre for Epidemiology and Biostatistics, School of Population and Global Health, 85084The University of Melbourne, Parkville, VIC, Australia.
Mark JenkinsCentre for Epidemiology and Biostatistics, School of Population and Global Health, 85084The University of Melbourne, Parkville, VIC, Australia.ORCID https://orcid.org/0000-0002-8964-6160
Amsterdam University Medical Centers · NLThe University of Melbourne · AUFinnish Cancer Registry · FIAarhus University · DKErasmus MC · NLErasmus University Rotterdam · NLGGD Amsterdam · NLNetherlands Institute for Health Services Research · NLRegional Hospital Randers · DKUniversity of Dundee · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is the second most diagnosed cancer in men and women and second most common cause of cancer death in Australia; Australia's CRC incidence and mortality are among the world's highest. The Australian National Bowel Cancer Screening Program began in 2006; however, only 33% of those approached for the first time by the Program between 2018 and 2019 returned the kit. Of the 5.7 million kits sent during this period, only 44% were returned. Our aim was to identify practices and features of national bowel cancer screening programs in countries with similar programs but higher screening participation, to identify potential interventions for optimising Australian CRC screening participation.

methodsWe searched published and grey literature for CRC screening programs reporting at least 50% screening participation using postal invitation and free return of iFOBT home kits. Interviews were conducted with cancer registry staff and academic researchers, focused on participant and practitioner engagement in screening.

resultsNational programs in Netherlands, Scotland, Denmark, and Finland reported over 50% screening participation rates for all invitation rounds. Shared characteristics include small populations within small geographic areas relative to Australia; relatively high literacy; a one-sample iFOBT kit; national registration systems for population cancer screening research; and screening program research including randomised trials of program features.

conclusionsApart from the one-sample kit, we identified no single solution to persistent Australian low uptake of screening. Research including randomised trials within the program promises to increase participation. IMPACT: This screening program comparison suggests that within-program intervention trials will lead to increased Australian screening participation.

Indexed as

Colorectal NeoplasmsEarly Detection of CancerAustraliaFemaleHumansMaleMass ScreeningOccult Bloodcolorectal cancerepidemiologyhelth carepopulationscreening

Identifiers

PMID35969473
PMCPMC9381723
OpenAlexW4291620267

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.